Class action complaint against Prilosec OTC
This article was originally published in The Tan Sheet
Executive Summary
An Ohio man claims he and hundreds of others suffered food-borne illnesses as a result of taking the proton pump inhibitor and because drug originator AstraZeneca and marketer Procter & Gamble "intentionally and uniformly hid from consumers" evidence of the side effect. Thomas Mitchell says in the complaint filed May 29 in the U.S. District Court for the Southern District of Ohio, Eastern Division, that he became ill after meals while taking Prilosec OTC. A P&G spokesman said in an e-mail that FDA "did not recommend any labeling regarding a link between Prilosec OTC and food poisoning" during the Rx-to-OTC switch review process
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.